Hydroxychloroquine retinopathy in patients with Rheumatic Diseases.
Not Applicable
- Conditions
- Health Condition 1: M138- Other specified arthritis
- Registration Number
- CTRI/2020/10/028459
- Lead Sponsor
- Dr Arindam Nandy Roy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Able to provide signed consent form.
Subjects clinically diagnosed to have rheumatic and musculoskeletal diseases.
Subjects willing to take HCQ for long duration
Exclusion Criteria
1. Preexisting ocular conditions of the anterior segment or the retina causing defective vision.
2. Are taking a medication other than HCQ with retinotoxic side effects (Tamoxifen).
3. Known hypersensitivity to 4-aminoquinoline compounds (such as Chloroquine or hydroxychloroquine).
4. Previous exposure to HCQ.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify the incidence and risk factors of retinopathy in patients of rheumatic and musculoskeletal diseases using long term HCQ by modern screening methods.Timepoint: After 01 year( later each year )
- Secondary Outcome Measures
Name Time Method Skin hyper pigmentationTimepoint: after 06 months